Javier Pinilla-Ibarz, MD, PhD

H Lee Moffitt Cancer Center & Research Institute

N/A

Poster(s):

• 1026 - Targeting the pro-inflammatory protein S100-A9 in Chronic Lymphocytic Leukemia

• 1037 - Activation of S100-A9/EMMPRIN axis triggers survival/proliferation pathways in leukemic cells. A novel target for chronic lymphocytic leukemia

• 1058 - T-cell Transcriptional and Mitochondrial Fitness Reprogramming in CLL Using PI3Kδ Inhibitors

• 1119 - Treatment Strategies and Outcomes for Double Refractory chronic lymphocytic leukemia; A single center experience

• 1155 - Loss of AID exacerbates the malignant progression of CLL

• 3003 - COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330)